Durata nets $46.3m for dalbavancin filings
This article was originally published in Scrip
Executive Summary
Durata Therapeutics, which has been a public company only since July, raised net proceeds of $46.3 million on 12 April to fund US and EU applications for marketing approval and commercial preparations for its once-weekly intravenous antibiotic dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI).